Abstract
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for multiple hematologic malignancies, demonstrating a clear curative potential in select cases. Since 2017, 7 CAR T-cell products have indications approved by the Food and Drug Administration, and research is continuously evolving with the intent of enhancing CAR T-cell efficacy while reducing side effects and the risk of relapse. Nuclear medicine has played a crucial role throughout this optimization process, assisting initial staging, treatment response assessment, and adverse-effect monitoring. This review provides an introduction to CAR T-cell therapy and highlights goldstandard nuclear medicine practices and imaging innovations for use in the care of oncology patients. Additionally, it emphasizes the need for continuing innovation in medical imaging as the field progresses.
| Original language | English |
|---|---|
| Pages (from-to) | 1021-1031 |
| Number of pages | 11 |
| Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine |
| Volume | 67 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- CAR T-cell
- hematologic malignancies
- immunotherapy-related toxicity
- nuclear medicine
- therapy response assessment
Fingerprint
Dive into the research topics of 'CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver